A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
The objective of this study was to evaluate the safety and efficacy of multiple doses of
upadacitinib monotherapy versus placebo in the treatment of adults with moderate to severe
atopic dermatitis (AD).